Trial Profile
Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TYCO1
- Sponsors GlaxoSmithKline; GSK
- 25 May 2011 New trial record